PMV Pharmaceuticals Inc., a Cranbury-based company focused on drug cancer treatments, announced on Wednesday it has appointed Dr. Leila Alland as its new chief medical officer.
“Dr. Alland’s depth of experience and proven leadership in shepherding innovative products from pre-clinical development through approval will be critical as we advance toward the clinic,” David Mack, CEO and president, PMV Pharma, said. “We are delighted to welcome Dr. Alland to our team. Her rich background in leading oncology clinical trials and drug development will help define the development strategies for our multiple programs.”
Alland, who has more than 25 years of experience in oncology, most recently served as the chief medical officer at Affimed. During her career, she held leadership roles at Tarveda Therapeutics, AstraZenica, Bristol-Myers Squibb, Novartis and Shering-Plough, where she contributed to multiple successful drug approvals.
“PMV Pharma is at the forefront of developing transformational products in oncology,” Alland said. “I am thrilled to join the PMV Pharma team at this important juncture, working alongside PMV Pharma’s highly skilled scientific team to help develop and deliver products to patients in need.”
